A practical reference on Reference standard: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-22. Anything still debated is marked as such rather than presented as settled.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
=== Breast feeding === Pantoprazole has been found to pass through the breast milk. Additionally, in rodent cancer studies, pantoprazole has been shown to potentially cause tumor growth. The clinical relevance of the finding is unknown, but risks and benefits are recommended for consideration in determining the use of therapy for the mother and child.
==== Declined ==== Grant Moody, Bexar County commissioner from the 3rd precinct Kyle Sinclair, former vice chair of the Bexar County Republican Party, nominee for the 20th district in 2022, and candidate for the 28th district in 2024 (ran in the 21st district) Marc Whyte, San Antonio city councilor from the 10th district (2023–present) and candidate for Texas's 121st House of Representatives district in 2018 (endorsed Lujan)
==== New fiscal control framework ==== Due to the provision included in the Transition constitutional amendment proposal, the government needed to submit to the National Congress a new fiscal framework to replace the spending ceiling, the government soon presented the proposal to the congress, which was accepted on 22 August. With the new law coming into effect, it established a floor and ceiling for the real growth of tax expenditures of 0.6% and 2.5% respectively; investments now also have a minimum correction floor at the level of inflation; furthermore, growth in fiscal spending is limited to 70% of the growth in government revenues of the previous year; the new framework also determines the application of gradual spending containment triggers in the case where the government is systematically unable to meet fiscal targets. With approval, the government said it hoped to be able to eliminate the primary deficit in 2024 and obtain surpluses of 0.5% and 1% of GDP in 2025 and 2026, respectively; the expectations were seen with skepticism not only by the market, but also by members of the government itself and parliamentarians. Lula himself later stated that the 2024 target is unlikely to be achieved, defending the expansion of spending on public works, even at the expense the increase in debt.
paucimannosylation, addition of simple glycans, primarily containing mannose and N-acetylglucosamine (GlcNAc), to asparagine residues O-GlcNAc, addition of N-acetylglucosamine to serine or threonine residues in a β-glycosidic linkage polysialylation, addition of polysialic acid (PSA) to neural cell adhesion molecule (NCAM) hydroxylation: addition of an oxygen atom to the side-chain of a Pro or Lys residue iodination: addition of an iodine atom to the aromatic ring of a tyrosine residue (e.g. in thyroglobulin) nucleotide addition such as ADP-ribosylation persulfidation, the addition of a sulfhydryl group onto a thiol group of a cysteine residue to form a hydropersulfide phosphate ester (O-linked) or phosphoramidate (N-linked) formation phosphorylation, the addition of a phosphate group, usually to serine, threonine, and tyrosine (O-linked), or histidine (N-linked) adenylylation, the addition of an adenylyl moiety, usually to tyrosine (O-linked), or histidine and lysine (N-linked) uridylylation, the addition of an uridylyl-group (i.e.
Sources: en.wikipedia.org
=== Kröhnke pyridine synthesis === In the Kröhnke pyridine synthesis, an N-pyridine-substituted methyl ketone is used as the reactant. This compound enters the keto-enol equilibrium and reacts with an enone via a Michael addition. A 1,5-dicarbonyl compound is formed, one carbonyl group of which is replaced by ammonia (or a synthesis equivalent) to form an imine. This intermediate subsequently cyclizes to give a pyridine. The reaction is named after Fritz Kröhnke, who developed it for the preparation of 2,4,6-triarylpyridines and published it in 1961.
The breast augmentation procedures realised by way of IMF augmentation (through the inframammary fold), of the TABA augmentation via the armpit (trans-axillary breast augmentation), and of the TUBA augmentation via the navel (trans-umbilical breast augmentation) avoid the nipple-areola complex in order to preserve the tactile sensitivity of the areola and the breastfeeding functions. Moreover, two conditions most affect and interfere with the functioning of the lactiferous ducts: (i) the subglandular implantation of the prosthetic breast, and (ii) the implantation of oversized prosthetic-breasts. Therefore, the implantation of small prosthetic breasts and a submuscular implant-pocket are the breast-augmentation surgeries that least thwart the breastfeeding function.
==== Staging ==== Non-cachexia (0–2 points) – No major weight loss or problems with appetite. Pre-cachexia (3–4 points) – Mild weight loss and appetite issues. Early treatment at this stage might slow progression of cachexia. Cachexia (5–8 points) – Significant muscle loss that is difficult to reverse and affects daily function. Refractory cachexia (9–12 points) – Severe weight and muscle loss with poor response to treatment and a life expectancy of less than 3 months. The Cachexia SCOre (CASCO) is another scoring system that looks at weight loss, inflammation, metabolism, immune function, physical ability, appetite, and quality of life to provide a more detailed assessment.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.